Tests SAL0140 doses in adults with uncontrolled high blood pressure
Compares different doses of SAL0140 with placebo in adults with uncontrolled hypertension.
Plain-language title generated from the registry record
Registry title: A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07654140, who can take part
Where in China
- Beijing Anzhen Hospital, Capital Medical UniversityBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Trial code
- NCT07654140
- Record updated
- 17 June 2026
- Original description
This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in uncontrolled hypertension.Read full original descriptionShow less
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension
This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in uncontrolled hypertension.
Inclusion: Patients 18-75 years old, male or female; Mean seated systolic blood pressure (msSBP) at screening was ≥140 mmHg and <180 mmHg; Meet either item A or B at screening: A. Uncontrolled hypertension (uHTN); B. Resistant hypertension (rHTN); Mean seated systolic blood pressure (msSBP) prior to randomization was ≥140 mmHg and <180 mmHg; Voluntarily participate in this study and sign the informed consent form; Agree to comply with contraception and fertility restrictions of this study.
Exclusion: Compliance with study drug during the run-in period was less than 80% or greater than 120%; Patients receiving hemodialysis or adhering to strict salt restriction therapy; Severe hypertension (msSBP ≥ 180 mmHg and/or msDBP ≥ 110 mmHg); malignant hypertension, hypertensive emergency, hypertensive crisis, hypertensive encephalopathy, etc; Hypertension complicated with the following conditions: acute coronary syndrome, myocardial infarction, percutaneous coronary intervention, stroke; Positive results for any of human immunodeficiency virus antibody (HIV), hepatitis C virus antibody (HCV), treponema pallidum antibody (TP); or positive hepatitis B surface antigen (HBsAg) with HBVDNA ≥ 1000 IU/mL; Patients with active malignant tumors; History of adrenal insufficiency; History of solid organ or bone marrow transplantation; Gastrointestinal diseases or post-gastrointestinal surgery; Known or suspected hypersensitivity to aldosterone synthase inhibitors; known or suspected contraindications or hypersensitivity to background medications; History of drug abuse or alcohol abuse; Blood donation or significant blood loss.